SavedAdd your journal

Journals / Clinical and Experimental Health Sciences / 2021 / Cilt: 11 - Sayı: 3

The Effects of Cyclosporine and Tacrolimus on Gingiva and Alveolar Bone of Rats

Burcu Karaduman
Ilhami Celik
Ural Karaduman
Mihtikar Gursel
Pages
516–522
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Our results showed that Tac does not seem to cause GO and alveolar bone resorption.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs which is frequently used in organ transplantation.
📊
Key Findings & Data:The Control-I and Control-II groups received, subcutaneously, 1 ml/kg 0.9% NaCl, while the CsA-I and CsA-II groups received 10 mg/kg CsA daily, and the Tac-I and Tac-II groups 1.5 mg/kg Tac daily.
💡
Conclusion & Impact:Conclusions: Our results showed that Tac does not seem to cause GO and alveolar bone resorption.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Bone Resorption · Cyclosporine A · Gingival Overgrowth

Abstract

Objective: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs which is frequently used in organ transplantation. CsA can cause various side effects including gingival overgrowth (GO) and osteopenia. Tac has similar side effects to CsA but with different incidences. The aim of the present study was to evaluate and compare the effects of CsA and Tac on GO and alveolar bone resorption in rats. Methods: Sixty mature male rats were randomly and equally allocated into six groups, as follows: Control-I, Control-II, CsA-I, CsA-II, Tac-I and Tac-II. The Control-I and Control-II groups received, subcutaneously, 1 ml/kg 0.9% NaCl, while the CsA-I and CsA-II groups received 10 mg/kg CsA daily, and the Tac-I and Tac-II groups 1.5 mg/kg Tac daily. The Control-I, CsA-I and Tac-I groups were sacrificed on the 16th day and other groups on the 31st day. Histological and histomorphometric analysis of the buccal gingiva and tartrate-resistant acid phosphatase (TRAP) enzyme histochemistry of the alveolar bone were performed in the right mandibular segment of each animal. Results: GO was significantly greater in the groups administered CsA compared to the other groups (P0.05). CsA caused a significant increase in TRAP positivity (P0.05). Conclusions: Our results showed that Tac does not seem to cause GO and alveolar bone resorption. However, the deleterious side effects of Tac on the gingival tissues of rats may be time-related.

🔖

Cite This Article

Karaduman, B., Celik, I., Karaduman, U., Gursel, M. (2022). The Effects of Cyclosporine and Tacrolimus on Gingiva and Alveolar Bone of Rats. Clinical and Experimental Health Sciences, Cilt: 11 - Sayı: 3, 516–522. https://ajindex.com/articles/474237

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Dongari-Bagtzolou A, Cutler C. Drug-Associated Gingival Enlargement. J Periodontol [Internet]. 2004;75:1424–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16945041
  2. Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol. 1998 Jun;49(6):356–63.
  3. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Vol. 54, Drugs. Springer International Publishing; 1997. p. 925–75.
  4. Prabhu A, Mehta DS. A Morphologic Comparison of Gingival Changes Influenced by Cyclosporin and Tacrolimus in Rats: An Experimental Study. J Periodontol. 2006 Feb;77(2):265–70.
  5. Spolidorio LC, Holzhausen M, Spolidorio DMP, Nassar CA, Nassar PO, Muscará MN. Cyclosporin But Not Tacrolimus Significantly Increases Salivary Cytokine Contents in Rats. J Periodontol. 2005 Sep;76(9):1520–5.
  6. Martins L, Ventura A, Branco A, Carvalho MJ, Henriques AC, Dias L, et al. Cyclosporine versus tacrolimus in kidney transplantation: Are there differences in nephrotoxicity? In: Transplantation Proceedings. 2004. p. 877–9.
  7. James JA, Jamal S, Hull PS, Macfarlane T V., Campbell BA, Johnson RWG, et al. Tacrolimus is not associated with gingival overgrowth in renal transplant patients. J Clin Periodontol. 2001;28(9):848–52.
  8. Lima RB, Benini V, Sens YAS. Gingival Overgrowth in Renal Transplant Recipients: A Study Concerning Prevalence, Severity, Periodontal, and Predisposing Factors. Transplant Proc. 2008 Jun;40(5):1425–8. de Oliveira Costa F, Diniz Ferreira S, de Miranda Cota LO, da Costa JE, Aguiar MA. Prevalence, Severity, and Risk Variables Associated With Gingival Overgrowth in Renal Transplant Subjects Treated Under Tacrolimus or Cyclosporin Regimens. J Periodontol. 2006 Jun;77(6):969–75.
  9. Bader G, Lejeune S, Messner M. Reduction of Cyclosporine-Induced Gingival Overgrowth Following a Change to Tacrolimus. A Case History Involving a Liver Transplant Patient. J Periodontol. 1998 Jun;69(6):729–32.
  10. Andia DC, Nassar CA, Nassar PO, Guimarães MR, Cerri PS, Spolidorio LC. Treatment with tacrolimus enhances alveolar bone formation and decreases osteoclast number in the maxillae: A histomorphometric and ultrastructural study in rats. Histol Histopathol. 2008;23(10):1177–84.
  11. Kanda J, Izumo N, Furukawa M, Shimakura T, Yamamoto N, Takahashi HE, et al. Effects of the calcineurin inhibitors cyclosporine and tacrolimus on bone metabolism in rats. Biomed Res. 2018;39(3):13